Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer
Status:
Withdrawn
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
This phase I trial investigates the side effects and best dose of abexinostat and palbociclib
when given together with fulvestrant in treating patients with breast or gynecologic cancer.
Abexinostat may prevent tumor cells from growing and multiplying and may kill tumor cells.
Palbociclib may prevent or slow the growth of tumor cells when used with other anti-hormonal
therapy. Estrogen can cause the growth of breast and gynecologic tumor cells. Fulvestrant may
help fight breast or gynecologic cancer by blocking the use of estrogen by the tumor cells.
Giving abexinostat, palbociclib, and fulvestrant may work better in treating patients with
breast or gynecologic cancer.